The anti-obesity protein
![People make their way through snow in New York's Times Square, February 8, 2013. A blizzard slammed into the northeastern United States on Friday, snarling traffic, disrupting thousands of flights and prompting five governors to declare states of emergency in the face of a fearsome snowstorm. REUTERS/Keith Bedford (UNITED STATES - Tags: ENVIRONMENT TPX IMAGES OF THE DAY) - RTR3DIUQ](https://assets.weforum.org/article/image/large_K-k8-DTgCSoRQzgAmKMk8h8HVZBV8bbC7Y0V9UwA2q8.jpg)
Obesity is one of the biggest health problems afflicting the US. Image: REUTERS/Keith Bedford
![A hand holding a looking glass by a lake](/uplink.jpg)
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Biotechnology
Deadly Combo
According to the World Health Organization (WHO), obesity is one of the most common health conditions in the world. It affects more than 600 million adults and around 41 million children under the age of 5. Of these, more than 29 million are in the United States, according to the Center for Disease Control and Prevention (CDC).
The consequences of obesity can be as serious as heart disease, stroke, some types of cancer, and type 2 diabetes, which the CDC reports around 29 million Americans have. Now, researchers from the Catholic University of Louvain in Belgium may have found a way to halt the development of both type 2 diabetes and obesity in humans, using a recently discovered protein.
![Image 1](https://assets.weforum.org/editor/QzesPic0ox_qytQXZpiVWYxcndQsqPYWuUjG6Yuyo-I.jpg)
For 10 years now, scientists Patrice Cani, a WELBIO researcher at the Louvain Drug Research Institute, and Willem de Vos of the University of Wageningen in the Netherlands, have been studying a bacterium called Akkermansia muciniphila, and have realized that this bacteria is found in smaller levels in obese mice. Treating mice with A. muciniphila seemed to reverse several metabolic disorders that led to obesity.
An Unexpected Discovery
In a study published in the journal Nature Medicine, Cani and de Vos discovered something more. Since December 2015, Akkermansia-based treatment trials for humans have been ongoing. While the effects are yet to be conclusive, it’s clear that the treatment isn’t harmful to humans — after all, A. muciniphila is one of the more common gut bacteria.
Then something came up. They discovered that pasteurization had very positive effects on the bacterium. “Unexpectedly, we discovered that pasteurization of A. muciniphila enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice,” says the study.
Pasteurization, it would seem, makes the bacterium effective because it kills off everything else in A. muciniphila except for a protein — the genetically engineered version of it is called Amuc_1100. When tested on mice, this protein appeared to be good for the immune system, blocking toxins from reaching the bloodstream, and strengthening intestinal immunity.
Amuc_1100 is the key to how A. muciniphila can combat obesity in mice. In the near future, it’s expected to be able to do the same thing in humans.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Related topics:
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Global RisksSee all
John Scott and Debora Iannuzzi Zubler
July 4, 2024
Lubomir Varbanov and Xin Dai
June 25, 2024
David Elliott
June 18, 2024
Chunquan Zhu and Shivin Kohli
June 18, 2024
Svein Tyldum
June 17, 2024
Blake Moret and Kiva Allgood
June 7, 2024